Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prospects for Progressive MS Therapies Reviewed

Lancet; 2017 Apr 1; Ontaneda, Thompson, et al

Publish date:: April 18, 2017

Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting multiple sclerosis (RRMS), the gradual accumulation of disability that characterizes progressive MS seems to result more from diffuse immune mechanisms and neurodegeneration, according to a recent review. As a result, the 14 anti-inflammatory drugs that have regulatory approval for treatment of RRMS have little or no efficacy in progressive MS without inflammatory lesion activity. Some key points:

Effective therapies for progressive MS that prevent worsening, reverse damage, and restore function are a major unmet need.
In this series paper, researchers summarize the current status of therapy for progressive MS and outline prospects for the future.

Citation:

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357-1366. doi:10.1016/S0140-6736(16)31320-4.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,